These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1546 related articles for article (PubMed ID: 21685821)

  • 1. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography.
    Ozkol V; Alper E; Aydin N; Ozkol HF; Topal NB; Akpinar AT
    Nucl Med Commun; 2010 Feb; 31(2):128-36. PubMed ID: 19858768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy?
    Nguyen ML; Gervais DA; Blake MA; Mueller PR; Sahani DV; Hahn PF; Uppot RN
    AJR Am J Roentgenol; 2013 Aug; 201(2):433-8. PubMed ID: 23883226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
    Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
    J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic ultrasound - fine needle aspiration of 2-deoxy-2-[18F] fluoro-D-glucose avid lymph nodes seen on positron emission tomography- computed tomography -what looks like cancer may not always be so.
    Malik AI; Akhtar N; Loya A; Yusuf MA
    Cancer Imaging; 2014 Jul; 14(1):27. PubMed ID: 25608976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of CT attenuation values of focal 18F-FDG avid breast lesions detected on whole-body PET-CT in postoperative breast cancer patients.
    Plaza MJ; Collado-Mesa F; Bokhoor J; Alperin N; Yepes MM
    Breast J; 2014; 20(3):235-42. PubMed ID: 24750508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
    Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
    Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.
    Samarin A; Hüllner M; Queiroz MA; Stolzmann P; Burger IA; von Schulthess G; Veit-Haibach P
    Nucl Med Commun; 2015 Dec; 36(12):1165-73. PubMed ID: 26397999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
    Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
    Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colonoscopic Findings in Patients With Incidental Colonic Focal FDG Uptake.
    Keyzer C; Dhaene B; Blocklet D; De Maertelaer V; Goldman S; Gevenois PA
    AJR Am J Roentgenol; 2015 May; 204(5):W586-91. PubMed ID: 25905966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis.
    Patel P; Finger PT
    Am J Ophthalmol; 2012 Apr; 153(4):661-8. PubMed ID: 22264690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
    Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
    Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.